Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment

977
64
Favorite

Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment

seekingalpha2022-01-30

In solidarity with the selloff in the biotech space, Moderna has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

977

Report

Comment（64）

Thomas9413
·2022-01-31
Great
Reply
2
Report
claratan
·2022-01-31
Wow
Reply
3
Report
kh93
·2022-01-31
Great
Reply
3
Report
Ah Deck
·2022-01-31
Bad news about Moderna ...pls like
Reply
1
Report
jian9182
·2022-01-31
Hi
Reply
4
Report
MHh
·2022-01-31
Don't worry. Many governments will still givein to fear and recommend/ mandate boosters[Duh]
Reply
6
Report
WannaBluffy
·2022-01-31
Like
Reply
3
Report
jian9182
·2022-01-31
Hi
Reply
3
Report
seojun
·2022-01-31
Hmmm i feel the technology can be used to make more vaccines
Reply
4
Report
BlueDragon
·2022-01-31
Like
Reply
4
Report
丰人
·2022-01-31
Like
Reply
5
Report
fysx49
·2022-01-31
mRNA just starting to shine.. Moderna is good for long term investment
Reply
6
Report
Enghui
·2022-01-31
👍
Reply
8
Report
angskk
·2022-01-31
Like pls thks
Reply
4
Report
Calculator88
·2022-01-31
Like
Reply
4
Report
Damien111
·2022-01-31
Like
Reply
3
Report
1nquisit0
·2022-01-31
Please like
Reply
6
Report
ramius75
·2022-01-31
🤔
Reply
3
Report
AudTKH
·2022-01-31
K
Reply
3
Report
MN27
·2022-01-31
Like pls
Reply
5
Report
Fold Replies
- IvanOon:
  Done
  2022-01-31
  Reply
  Report
- Cheryi:
  ok
  2022-01-31
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2207801110?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-30 13:50","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2207801110","market":"us","top_or_hot":-1,"title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","media":"seekingalpha","content":"<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","article_id":"2207801110","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","pubTimestamp":1643521816,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","BK4504":"桥水持仓","MRNA":"Moderna, Inc."},"translate_title":"在喜忧参半的情绪中，莫德纳跌至标普500谷底","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9093892624,"gmtCreate":1643586892169,"gmtModify":1676533832811,"author":{"id":"3585385605908328","authorId":"3585385605908328","name":"Thomas9413","avatar":"https://static.tigerbbs.com/effcfaa82ddb11a4fa57136b2a6f8351","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":1,"crmLevelSwitch":0,"idStr":"3585385605908328","authorIdStr":"3585385605908328"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093892624","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093899126,"gmtCreate":1643586078753,"gmtModify":1676533832653,"author":{"id":"3573731928321338","authorId":"3573731928321338","name":"claratan","avatar":"https://static.tigerbbs.com/9c6bbdac9048ff2e4b740f272576e2be","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3573731928321338","authorIdStr":"3573731928321338"},"htmlText":"Wow&nbsp;","listText":"Wow&nbsp;","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093899126","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093890588,"gmtCreate":1643586044059,"gmtModify":1676533832645,"author":{"id":"3582146721848049","authorId":"3582146721848049","name":"kh93","avatar":"https://static.tigerbbs.com/3c9407513f02fb16a39206078ff5e453","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582146721848049","authorIdStr":"3582146721848049"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093890588","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093808075,"gmtCreate":1643585152257,"gmtModify":1676533832471,"author":{"id":"4098445225447010","authorId":"4098445225447010","name":"Ah Deck","avatar":"https://static.tigerbbs.com/0e52eb1e14e0f630d24f1687ea546cd8","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4098445225447010","authorIdStr":"4098445225447010"},"htmlText":"Bad news about Moderna ...pls like&nbsp;","listText":"Bad news about Moderna ...pls like&nbsp;","text":"Bad news about Moderna ...pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093808075","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093803034,"gmtCreate":1643584909646,"gmtModify":1676533832419,"author":{"id":"3582791933425189","authorId":"3582791933425189","name":"jian9182","avatar":"https://static.tigerbbs.com/6abc03a95d65182e1abd5ba6b362a136","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3582791933425189","authorIdStr":"3582791933425189"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093803034","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093800334,"gmtCreate":1643584681072,"gmtModify":1676533832368,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"4091758936365950","authorIdStr":"4091758936365950"},"htmlText":"Don't worry. Many governments will still givein to fear and recommend/ mandate boosters[Duh]&nbsp;","listText":"Don't worry. Many governments will still givein to fear and recommend/ mandate boosters[Duh]&nbsp;","text":"Don't worry. Many governments will still givein to fear and recommend/ mandate boosters[Duh]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093800334","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093177690,"gmtCreate":1643584574983,"gmtModify":1676533832347,"author":{"id":"3586986998667843","authorId":"3586986998667843","name":"WannaBluffy","avatar":"https://static.tigerbbs.com/1dd14463a45a95644b65d2bd68777ecd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586986998667843","authorIdStr":"3586986998667843"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093177690","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093174685,"gmtCreate":1643584462476,"gmtModify":1676533832315,"author":{"id":"3582791933425189","authorId":"3582791933425189","name":"jian9182","avatar":"https://static.tigerbbs.com/6abc03a95d65182e1abd5ba6b362a136","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3582791933425189","authorIdStr":"3582791933425189"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093174685","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093172758,"gmtCreate":1643584136914,"gmtModify":1676533832283,"author":{"id":"4087771643270940","authorId":"4087771643270940","name":"seojun","avatar":"https://static.tigerbbs.com/3bd9ce06b0a58d0a81582641f6566970","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4087771643270940","authorIdStr":"4087771643270940"},"htmlText":"Hmmm i feel the technology can be used to make more vaccines","listText":"Hmmm i feel the technology can be used to make more vaccines","text":"Hmmm i feel the technology can be used to make more vaccines","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093172758","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093176176,"gmtCreate":1643583883862,"gmtModify":1676533832243,"author":{"id":"4087932884013320","authorId":"4087932884013320","name":"BlueDragon","avatar":"https://static.tigerbbs.com/431c326e19a16844e147d10866565f27","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4087932884013320","authorIdStr":"4087932884013320"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093176176","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093176304,"gmtCreate":1643583865035,"gmtModify":1676533832240,"author":{"id":"4088035849823630","authorId":"4088035849823630","name":"丰人","avatar":"https://static.tigerbbs.com/35bfaa2970044533bc9763d63a71e1dd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088035849823630","authorIdStr":"4088035849823630"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093176304","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093173714,"gmtCreate":1643583305054,"gmtModify":1676533832187,"author":{"id":"3577580458147788","authorId":"3577580458147788","name":"fysx49","avatar":"https://static.tigerbbs.com/fe5937c0ada861e9603ef8a12ae3e445","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3577580458147788","authorIdStr":"3577580458147788"},"htmlText":"mRNA just starting to shine.. Moderna is good for long term investment","listText":"mRNA just starting to shine.. Moderna is good for long term investment","text":"mRNA just starting to shine.. Moderna is good for long term investment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093173714","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093179608,"gmtCreate":1643582967777,"gmtModify":1676533832146,"author":{"id":"4091077213138580","authorId":"4091077213138580","name":"Enghui","avatar":"https://static.tigerbbs.com/b2cae67246a011bb13c2be0fd7648865","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"4091077213138580","authorIdStr":"4091077213138580"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093179608","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093170779,"gmtCreate":1643582897094,"gmtModify":1676533832154,"author":{"id":"3575447019432232","authorId":"3575447019432232","name":"angskk","avatar":"https://static.tigerbbs.com/14993a1ab2e959534763e33dc2415981","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575447019432232","authorIdStr":"3575447019432232"},"htmlText":"Like pls thks","listText":"Like pls thks","text":"Like pls thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093170779","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093145604,"gmtCreate":1643582183123,"gmtModify":1676533831929,"author":{"id":"3583354852168828","authorId":"3583354852168828","name":"Calculator88","avatar":"https://static.tigerbbs.com/5a2c4088dca8986e0e57d7f1f47c11bc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583354852168828","authorIdStr":"3583354852168828"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093145604","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093142039,"gmtCreate":1643581769697,"gmtModify":1676533831887,"author":{"id":"3581590268956264","authorId":"3581590268956264","name":"Damien111","avatar":"https://community-static.tradeup.com/news/79328dd256df8bc25949678982e26fc3","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3581590268956264","authorIdStr":"3581590268956264"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093142039","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093148267,"gmtCreate":1643581564250,"gmtModify":1676533831857,"author":{"id":"3553900041025922","authorId":"3553900041025922","name":"1nquisit0","avatar":"https://static.tigerbbs.com/3c22511f65f9157a35a7f105f2b1d9bf","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3553900041025922","authorIdStr":"3553900041025922"},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093148267","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093140789,"gmtCreate":1643580751637,"gmtModify":1676533831769,"author":{"id":"3586470645934044","authorId":"3586470645934044","name":"ramius75","avatar":"https://community-static.tradeup.com/news/9bf23146914ff935921288dd903ce4fa","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3586470645934044","authorIdStr":"3586470645934044"},"htmlText":"🤔","listText":"🤔","text":"🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093140789","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093155665,"gmtCreate":1643579671980,"gmtModify":1676533831677,"author":{"id":"3575582076363736","authorId":"3575582076363736","name":"AudTKH","avatar":"https://static.tigerbbs.com/e4905e1cd622b8faa04ad4125cd04a83","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575582076363736","authorIdStr":"3575582076363736"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093155665","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":633080190,"gmtCreate":1643577372156,"gmtModify":1676532666625,"author":{"id":"3585973860502184","authorId":"3585973860502184","name":"MN27","avatar":"https://static.tigerbbs.com/0a11b544b50a084b6af0533c0b412c51","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585973860502184","authorIdStr":"3585973860502184"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/633080190","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://ttm.financial/m/news/2207801110?lang=&edition=fundamental","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100365269,"gmtCreate":1643580572131,"gmtModify":1663243008336,"authorId":3569354683318638,"author":{"id":3569354683318638,"idStr":"3569354683318638","authorId":3569354683318638,"name":"IvanOon","avatar":"https://static.tigerbbs.com/7e332af04c99b1ae0ca2131246646a93","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":633080190,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":7221332,"gmtCreate":1643584766045,"gmtModify":1663239702026,"authorId":3568940106394782,"author":{"id":3568940106394782,"idStr":"3568940106394782","authorId":3568940106394782,"name":"Cheryi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":633080190,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":977,"commentSize":64,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}